Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.
Khavinson. V Kh VK; Kuznik. B I BI; Trofimova. S V SV; Volchkov. V A VA; Rukavis...
Adding the thymus‑derived peptide thymalin to regular COVID‑19 treatment helped patients lower inflammation markers (IL‑6, CRP), blood clot risk (D‑dimer), and improve T‑cell numbers faster than standard care alone.